Latest and Past News
-
UPDATE – Supply of DDAVP injectable discontinued
Ferring says supply of DDAVP injectable to return in “one to two months” Montreal, June 23, 2021 – Ferring Canada, in discussions with the Canadian...
-
Novel treatments in bleeding disorders: The European Haemophilia Consortium Review
CLICK HERE to access the June 2021 review of novel treatments in haemophilia and other bleeding disorders by the European Haemophilia Consortium.
-
CHS 5-year strategic framework officially launched!
The CHS is pleased to share its brand new five-year strategic framework following an extensive strategic planning exercise held in 2020. The strategy is expressed...
-
UPDATED Access to Hemlibra: Decisions from provincial/territorial governments expected in coming weeks
On May 25, 2021, Canadian Blood Services (CBS) released its report on emicizumab (Hemlibra) to the provincial/territorial (P/T) Ministers of Health (except Quebec), recommending eligibility...
-
CBS recommends emicizumab (Hemlibra) to Ministers of Health
On May 25, 2021, Canadian Blood Services (CBS) released its recommendation on emicizumab (Hemlibra) to the provincial/territorial Ministers of Health. CBS recommends that emicizumab be listed...
-
Coagulation products | Current and in the pipeline
Updated charts for products in the pipeline have been uploaded on the CHS website. The CHS publishes four charts, one each for clotting factor concentrates,...
-
Celebrating a birthday!
CHS CONTACT is a year old! And what a year it has been on the news front! If we could have chosen the best year...
-
The World Federation of Hemophilia/European Haemophilia Consortium statement on very rare adverse events with COVID-19 vaccines
April 12, 2021 — Please see the World Federation of Hemophilia/European Haemophilia Consortium statement on very rare adverse events with COVID-19 vaccines: www1.wfh.org/docs/website/en/News/WFH-EHC-Statement-on-EMA-April2021.pdf The key...
-
Medical, nursing and patient groups unite to contest INESSS report on Hemlibra
Montreal, March 29, 2021 – Medical and patient groups in Quebec and across Canada have united in their rejection of the recommendation by Quebec’s health...
-
Best Medicines Coalition submission on high-cost drugs for rare diseases
The Best Medicines Coalition (BMC) is a national alliance of patient organizations, together representing millions of patients, with a shared goal of equitable, timely and...
-
CHS replies to Quebec’s INESSS following its shocking report on the funding of Hemlibra
The Institut national d’excellence en santé et en services sociaux (INESSS) released its recommendation on funding Hemlibra (emicizumab) for the treatment of severe hemophilia A...
-
Fitusiran trial restarts with new controls
BRUSSELS – During the European Association for Haemophilia and Allied Disorders (EAHAD) virtual congress session on the latest clinical trial, Dr. Shauna Anderson, representing Sanofi,...
-
Community awaits decisions on access to Hemlibra
Montreal, February 4, 2021 – The hemophilia community is awaiting decisions by Canadian health authorities on access to Hemlibra for people with hemophilia A without...
-
Results from a CHS/Novo Nordisk Psychosocial Research Program project now published
In 2018, Jennifer King, social worker at the Saskatchewan Health Authority in Saskatoon, was awarded a grant through the CHS/Novo Nordisk Psychosocial Research Program for...